Gator SCALES-WHF: SubCutaneous Administration of Lasix to Eliminate Symptoms of Worsening Heart Failure

Phase 4

Not yet recruiting

• Conditions: Heart Failure; Volume Overload
• Interventions: Drug: Lasix ONYU

• Registration Number: NCT06979726
• Lead Sponsor: University of Florida

Brief Summary

The primary objective of the study is to develop, implement, and evaluate a site-specific clinical pathway for at-home treatment of eligible patients presenting to the clinic with worsening heart failure.

The secondary objectives are:

1. To evaluate patient factors related to parenteral decongestion at home.

2. To evaluate the safety and device operation of Lasix ONYU treatment under circumstances that mimic real-world use.

3. To identify opportunities for process improvement before the routine implementation of the new clinical pathway.

Detailed Description

We will conduct an open-label, non-comparative, real-world study to evaluate the effectiveness and feasibility of at-home decongestion treatment using Lasix ONYU in patients with worsening heart failure (WHF). During a clinical visit at the UF Heart Failure Clinic, Emergency Department, or Clinical Decision Unit, we will assess whether a patient meets eligibility criteria for the study.

Study Timeline

• Status Verified: 2025-05
• Study First Submitted: 2025-05-13
• Study First Submitted QC: 2025-05-13
• Last Update Submitted: 2025-05-13
• Study First Posted: 2025-05-20
• Last Update Posted: 2025-05-20
• Study Start: 2025-07-01
• Primary Completion: 2025-12-31
• Study Completion: 2026-01-31

Recruitment & Eligibility

• Status: NOT_YET_RECRUITING
• Sex: All
• Target Recruitment: 100

Inclusion Criteria

1. Age 18 or above

2. Previously diagnosed with Congestive Heart Failure (HFpEF or HFrEF)

3. Fluid overload due to worsening HF requiring parenteral diuretic treatment as assessed by at least 2 of the following:

   1. BNP > 200
   2. JVP > 10cmH20
   3. Presence of S3
   4. LE Edema
   5. Weight gain of > 5lbs in the past 5 days

4. Failed oral uptitration of loop diuretic over the prior 5 days or presented with symptoms too advance to justify additional oral uptitration attempts to resolve congestion symptoms.

5. Expected to require a minimum of three days of parenteral diuretic treatment

6. Written informed consent

7. Able and willing to operate Lasix ONYU and comply with study requirements or has a caregiver who can assume these roles.

Exclusion Criteria

1. Age above 80 years
2. Unable or unwilling to provide informed consent.
3. Any medical condition or circumstances that would require further clinical investigation or hospitalization
4. Presence or history of electrolyte abnormalities that may be exacerbated by parenteral loop diuretic treatment
5. Home or current living environment not suitable for outpatient management and diuresis
6. Pregnant or breastfeeding
7. Unable to comply with clinic-required follow up procedure
8. Baseline chronic renal disease with CKD Stage V
9. Any surgical or medical condition which, in the opinion of the investigator, may pose an undue risk to the subject, interfere with participation in the study or which may affect the integrity of the data

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: SINGLE_GROUP

Arm && Interventions

Group	Intervention	Description
Lasix ONYU	Lasix ONYU	Patients receiving Lasix ONYU

Primary Outcome Measures

Name	Time	Method
Safety of Lasix ONYU Use	30 days	Adverse reactions, acute kidney injury

Secondary Outcome Measures

Name	Time	Method
Hospital Readmission	30 days	30 day readmission from time of Lasix ONYU administration